SHTDF News and Press, Sinopharm Group Co. Ltd.

2025-07-24 00:20:00 ET Market Commentary Emerging market equities performed strongly during the first half of 2025, providing high absolute returns as well as diversification benefits relative to the U.S. equity market. While U.S. stocks have been hampered by uncertainty regarding t...

2025-05-21 09:15:00 ET Summary In the first quarter, the Emerging Markets Equity Portfolio rose in absolute terms and outperformed its benchmark, the MSCI Emerging Markets Index. Stock selection in the industrials and financials sectors boosted relative performance, as did stock s...

2025-04-17 11:06:04 ET Summary I maintain a Neutral rating for Sinopharm Group, considering sector-specific challenges and the company's favorable guidance. SHTDF's peers Shanghai Pharmaceuticals and China Resources Pharmaceutical have highlighted headwinds like lower drug prices ...

2025-04-16 07:00:00 ET Summary Emerging market equities performed strongly during the first quarter of 2025, providing diversification benefits as the U.S. equity market slumped on concerns about the potential for trade wars, higher inflation, and restructured trade and military allia...

2025-02-20 11:45:00 ET Summary The Allspring Emerging Markets Equity Income Fund outperformed the MSCI Emerging Markets (EM) Index (Net) for the quarter that ended December 31, 2024. At the sector level, stocks within the materials, energy, and industrials sectors served as relati...